Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Abide Therapeutics
San Diego, California, United Statesabidetx.com ↗
- Ownership
- Private
- Employees
- ~40
- Development stage
- Other
01
Overview
Abide’s lead program, ABX‑1431—a potent and selective MGLL inhibitor—was in Phase 2 trials for Tourette syndrome and entering Phase 2 for other neurological diseases at the time of its acquisition by Lundbeck. The company’s platform enabled rapid identification and development of small-molecule inhibitors targeting the under-explored serine hydrolase enzyme family. No commercial products were reported prior to acquisition.
- Therapeutic areas
- ImmunologyPsychiatryNeurologyMetabolic Disorders
- Modalities
- Small molecules (notably serine hydrolase inhibitors)
- Industry
- Biotech
02
Partnerships
Celgene – strategic collaboration on inflammation/immunology drug discovery/developmentMerck & Co. – partnership to develop small-molecule therapies for metabolic disease/type II diabetes
Beyond the preview
Go deeper on Abide Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Abide Therapeutics.